SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " edgewise " 4 found 🔀 AI-powered Shuffle
Sign in to save shuffle history.
Servier to buy Edgewise's muscular dystrophy business for $2.65bn
Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn.
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
/PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today...
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
/PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of...
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
/PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into an agreement to...